Overview of This Research:
The study involved four major activities to estimate the current size of the patient blood management market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.
Secondary Research:
This research study involved the extensive use of secondary sources, directories, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva), along with government databases, which were used to identify and collect information for this method-based, market-oriented, and commercial study of the market.
In-depth interviews were conducted with various primary respondents that mainly include key industry participants, medical practitioners, subject-matter experts (SMEs), C-level and D-level executives of key market players, and industry consultants to obtain and verify critical qualitative and quantitative information as well as to assess prospects of the market.
Download PDF Brochure@
Primary Research:
Extensive primary research was conducted after acquiring knowledge about the patient blood management market scenario through secondary research. A significant number of primary interviews were conducted with both the demand (healthcare providers, blood bank operators, physicians, and blood bank technicians) and supply sides (developers, manufacturers, and distributors of patient blood management products). The primaries interviewed for this study include experts from the patient blood management industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering patient blood management products across the globe), purchase managers in healthcare provider organizations, blood banks, blood collection centers, plasma collection centers, and CROs.
The whole blood segment is projected to hold the largest share of the market, by component, during the forecast period of 2019 to 2024
By component, the patient blood management market is segmented into whole blood and blood components. The whole blood segment is expected to hold a major share of the market during the forecast period. An increase in the number of surgical procedures coupled with rising incidences of blood-related disorders that require blood transfusion during treatment are the key factors supporting the market growth of this segment.
Blood banks were the key end users in the patient blood management market in 2019
On the basis of end users, the patient blood management market is segmented into hospitals and blood banks. The increasing number of blood donations has increased the need for proper management of blood. Blood banks are the key end users for various blood processing devices, blood collection devices, and blood storage devices. The key factors attributing to the growth of the blood banks segment include the growing awareness about blood donations, rising automation in blood banks, and the increase in the number of blood banks in developing countries.
The Asia Pacific region is expected to register significant growth during the forecast period of 2019-2024
The patient blood management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific blood management market is expected to register significant growth over the forecast period due to the modernization of healthcare infrastructure, increasing prevalence of chronic lifestyle diseases, and rising awareness about blood donation & blood safety. China accounted for a major share of the Asia Pacific market, owing to a large patient pool and favorable government guidelines to improve healthcare infrastructure in the country.
Request Sample Pages@
The major players in the market include Haemonetics Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo Corporation (Japan), Immucor, Inc. (US), B. Braun Melsungen AG (Ireland), Macopharma (US), bioMérieux SA (France), Asahi Kasei Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), Grifols, S.A. (Spain), F. Hoffmann-La Roche LTD (Switzerland), LivaNova PLC (UK), Danaher Corporation (US), Mediware Information Systems (US), Kawasumi Laboratories, Inc. (Japan), Haier Biomedical (China), Diatron (Hungary), and BAG Diagnostics GmbH (Germany), among others.
No comments:
Post a Comment